Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit
- PMID: 1539462
- DOI: 10.1016/0264-410x(92)90025-f
Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit
Abstract
Secretory antibodies in mucosal surfaces are known to play an essential role in protection against various infectious diseases. To enhance the production of such antibodies, influenza HA vaccine was inoculated intranasally into rabbits, together with cholera toxin B subunit (CTB) which is known to augment antibody response to an unrelated antigen. This combination resulted in high levels of serum IgG antibody responses against HA and CTB molecules, 3-4 weeks after inoculation, compared with the inoculation of HA vaccine alone. The adjuvant mechanism for CTB was studied by using Ussing chambers, in which nasal mucosa from rabbits were mounted. CTB was found to enhance the transepithelial flux of HA vaccine, from the mucosal side (lumen) into the serosal side (lamina propria), indicating that the permeability of the membrane was changed by CTB. Moreover, to achieve effective flux of HA vaccines, some interactions between the vaccine and CTB across the membrane were found, which may effect the effectiveness of the vaccine formulation. The results suggest that one of the mechanisms by which CTB enhances the production of mucosal antibody response is to enhance the transepithelial influx of vaccine into the nasal mucosa, where the cells involved in the antibody production are located. CTB may be used as a potent adjuvant to induce antibody response, by nasal vaccination, against pathogens impinging on mucosal surfaces.
Similar articles
-
Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.Vaccine. 1988 Oct;6(5):409-13. doi: 10.1016/0264-410x(88)90140-5. Vaccine. 1988. PMID: 2848377
-
Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.Vaccine. 1994 Apr;12(5):419-26. doi: 10.1016/0264-410x(94)90118-x. Vaccine. 1994. PMID: 8023550
-
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.Vaccine. 1990 Jun;8(3):243-8. doi: 10.1016/0264-410x(90)90053-o. Vaccine. 1990. PMID: 2363302
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
-
A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.Jpn J Infect Dis. 2000 Jun;53(3):98-106. Jpn J Infect Dis. 2000. PMID: 10957706 Review.
Cited by
-
The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide.Immunology. 1996 Dec;89(4):483-7. doi: 10.1046/j.1365-2567.1996.d01-790.x. Immunology. 1996. PMID: 9014810 Free PMC article.
-
Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.Infect Immun. 1999 Aug;67(8):4128-33. doi: 10.1128/IAI.67.8.4128-4133.1999. Infect Immun. 1999. PMID: 10417183 Free PMC article.
-
Optimal delivery of vaccines: clinical pharmacokinetic considerations.Clin Pharmacokinet. 1996 Jan;30(1):1-15. doi: 10.2165/00003088-199630010-00001. Clin Pharmacokinet. 1996. PMID: 8846624 Review. No abstract available.
-
Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.Infect Immun. 1993 May;61(5):1964-71. doi: 10.1128/iai.61.5.1964-1971.1993. Infect Immun. 1993. PMID: 8478086 Free PMC article.
-
Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.Immunology. 1996 Feb;87(2):179-85. doi: 10.1046/j.1365-2567.1996.462527.x. Immunology. 1996. PMID: 8698377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical